Device Trial Radar · NCT05414617
Safety of Use of Pandora for Patients Suffering From Gonarthrosis
Last checked: Nov 20, 2026Latest source record: Jun 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Jun 8, 2022
Primary completion
Jan 18, 2023
Study completion Jun 14, 2023
Sponsor
- Lead sponsor
- LabrhaNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Statitec
- First posted
- Jun 10, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 35 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The knee osteoarthritis is a frequent degenerative condition that mainly affects subjects over 60, population often weakened by numerous comorbidities and concomitant treatments, justifying the development of new therapies. The viscosupplementation is a symptomatic treatment for knee osteoarthritis ; the objective of this intra-articular injection of hyaluronic acid is to reduce knee pain and improve mobility. In practice, there are two protocols to administer viscosupplementation : in a single injection or in three injections performed weekly. The present clinical investigation has the objective to evaluate the safety of use of Pandora in a single injection or in three injections performed weekly.
Conditions
- Knee Osteoarthritis
Interventions
Intra-articular single injectionDevice
Both groups will receive their first injection after a selection visit ; first injection will be planned between 7 days to 30 days after to confirm the enrollment. The injection will be performed at Day 1.
Intra-articular three injectionsDevice
Both groups will receive their first injection after a selection visit ; first injection will be planned between 7 days to 30 days after to confirm the enrollment. The injections will be performed at Days 1, 8 and 15.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of adverse event attributable to the investigational Medical Device during the week following each injection.Time frame: 1 month
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Hôpital Nord Franche-Comté, HNFC
Belfort, France
Groupe Hospitalier de la Région Mulhouse Sud-Alsace, GHRMSA
Mulhouse, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.